Microarray analysis on human neuroblastoma cells exposed to aluminum, β 1-42-Amyloid or the β1-42-Amyloid aluminum complex

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Gatta, Valentina ^a,b   Drago, Denise ^c   Fincati, Karina ^c   Valenti, Maria Teresa ^d   Carbonare, Luca Dalle ^d   Sensi, Stefano L ^a,e,f   Zatta, Paolo ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b CeSI Center for Excellence on Aging   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Molecular Neurology Unit CeSI   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CALCIUM; GLUTAMIC ACID; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GLUTAMATERGIC TRANSMISSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; UPREGULATION; APOPTOSIS; DRUG EFFECT; GENETICS; INFLAMMATION; METABOLISM; NEUROBLASTOMA; PATHOLOGY; SYNAPTIC TRANSMISSION;

ALUMINUM; AMYLOID BETA-PEPTIDES; APOPTOSIS; CALCIUM; GENE EXPRESSION PROFILING; GLUTAMIC ACID; HUMANS; INFLAMMATION; MICROARRAY ANALYSIS; NEUROBLASTOMA; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; SYNAPTIC TRANSMISSION;

EID: 79551524309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015965     Document Type: Article

References (109)

1. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52.
2. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 31: 286-292.
3. Liu G, Huang W, Moir RD, Vanderburg CR, Lai B, et al. (2006) Metal exposure and Alzheimer's pathogenesis. J Struct Biol 155: 45-51.
4. Sensi SL, Paoletti P, Bush AI, Sekler I (2009) Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 10: 780-791.
5. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, et al. (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 6: 291-301.
6. Ricchelli F, Drago D, Filippi B, Tognon G, Zatta P (2005) Aluminum-triggered structural modifications and aggregation of beta-amyloids. Cell Mol Life Sci 62: 1724-1733.
7. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214.
8. Drago D, Bettella M, Bolognin S, Cendron L, Scancar J, et al. (2008) Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40: 731-746.
9. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173-2178.
10. Ricciarelli R, d'Abramo C, Massone S, Marinari U, Pronzato M, et al. (2004) Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life 56: 349-354.
11. Hoerndli FJ, Toigo M, Schild A, Gotz J, Day PJ (2004) Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem 335: 30-41.
12. Alexandrov PN, Zhao Y, Pogue AI, Tarr MA, Kruck TP, et al. (2005) Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis 8: 117-127; discussion 209-115.
13. Lukiw WJ, LeBlanc HJ, Carver LA, McLachlan DR, Bazan NG (1998) Run-on gene transcription in human neocortical nuclei. Inhibition by nanomolar aluminum and implications for neurodegenerative disease. J Mol Neurosci 11: 67-78.
14. Lukiw WJ, Percy ME, Kruck TP (2005) Nanomolar aluminum induces proinflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem 99: 1895-1898.
15. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61: 39-61.
16. Bataille N, Schmitt N, Aumercier-Maes P, Ollivier B, Lucas-Heron B, et al. (1994) Molecular cloning of human calmitine, a mitochondrial calcium binding protein, reveals identity with calsequestrine. Biochem Biophys Res Commun 203: 1477-1482.
17. Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, et al. (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 30: 2636-2649.
18. Malleret G, Haditsch U, Genoux D, Jones MW, Bliss TV, et al. (2001) Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell 104: 675-686.
19. Putney JW, Jr. (1986) A model for receptor-regulated calcium entry. Cell Calcium 7: 1-12.
20. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, et al. (2002) Prominent neurodegeneration and increased plaque formation in complementinhibited Alzheimer's mice. Proc Natl Acad Sci U S A 99: 10837-10842.
21. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, et al. (2007) Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A 104: 12011-12016.
22. Gerber U, Gee CE, Benquet P (2007) Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol 7: 56-61.
23. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283: 29615-29619.
24. Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, et al. (1997) Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Acta Neuropathol 94: 519-524.
25. Neumann S, Schobel S, Jager S, Trautwein A, Haass C, et al. (2006) Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein. J Biol Chem 281: 7583-7594.
26. Adlerz L, Holback S, Multhaup G, Iverfeldt K (2007) IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 282: 10203-10209.
27. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362: 329-344.
28. Aliev G, Palacios HH, Lipsitt AE, Fischbach K, Lamb BT, et al. (2009) Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res 16: 293-305.
29. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, et al. (2010) Earlystage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 7: 96-98.
30. Lipton SA (2007) Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 8: 621-632.
31. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, et al. (1999) Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284: 1845-1848.
32. Wu F, Yao PJ (2009) Clathrin-mediated endocytosis and Alzheimer's disease: an update. Ageing Res Rev 8: 147-149.
33. Kopec CD, Li B, Wei W, Boehm J, Malinow R (2006) Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J Neurosci 26: 2000-2009.
34. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, et al. (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913-922.
35. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, et al. (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34: 95-106.
36. Borsello T, Forloni G (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 13: 1875-1886.
37. Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, et al. (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol 26: 4327-4338.
38. Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766.
39. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, et al. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767.
40. Fahrenholz F, Gilbert S, Kojro E, Lammich S, Postina R (2000) Alphasecretase activity of the disintegrin metalloprotease ADAM 10. Influences of domain structure. Ann N Y Acad Sci 920: 215-222.
41. Hwang EM, Kim SK, Sohn JH, Lee JY, Kim Y, et al. (2006) Furin is an endogenous regulator of alpha-secretase associated APP processing. Biochem Biophys Res Commun 349: 654-659.
42. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286: 785-790.
43. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, et al. (2006) Activitydependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 311: 1008-1012.
44. Wang Y, Liu L, Xia Z (2007) Brain-derived neurotrophic factor stimulates the transcriptional and neuroprotective activity of myocyte-enhancer factor 2C through an ERK1/2-RSK2 signaling cascade. J Neurochem 102: 957-966.
45. Barbosa AC, Kim MS, Ertunc M, Adachi M, Nelson ED, et al. (2008) MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc Natl Acad Sci U S A 105: 9391-9396.
46. Zhang SJ, Zou M, Lu L, Lau D, Ditzel DA, et al. (2009) Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet 5: e1000604.
47. Kurochkin IV, Goto S (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345: 33-37.
48. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100: 4162-4167.
49. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, et al. (2000) Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290: 2302-2303.
50. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, et al. (2010) Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease. Arch Neurol.
51. Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner N, et al. (2010) Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One 5: e8764.
52. Miners JS, Baig S, Tayler H, Kehoe PG, Love S (2009) Neprilysin and insulindegrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 68: 902-914.
53. Morrison BE, Majdzadeh N, D'Mello SR (2007) Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64: 2258-2269.
54. Alberini CM (2009) Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 89: 121-145.
55. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
56. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328: 753-756.
57. Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, et al. (2006) Neuroprotection by histone deacetylase-related protein. Mol Cell Biol 26: 3550-3564.
58. Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269: 13057-13060.
59. Balsinde J, Shinohara H, Lefkowitz LJ, Johnson CA, Balboa MA, et al. (1999) Group V phospholipase A(2)-dependent induction of cyclooxygenase-2 in macrophages. J Biol Chem 274: 25967-25970.
60. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45: 205-213.
61. Schaeffer EL, Forlenza OV, Gattaz WF (2009) Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology (Berl) 202: 37-51.
62. Bazan NG, Colangelo V, Lukiw WJ (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69: 197-210.
63. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, et al. (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287: 2262-2267.
64. Derkach VA, Oh MC, Guire ES, Soderling TR (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci 8: 101-113.
65. Gu Z, Liu W, Yan Z (2009) β-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem 284: 10639-10649.
66. Roselli F, Hutzler P, Wegerich Y, Livrea P, Almeida OF (2009) Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PLoS One 4: e6011.
67. Mao L, Yang L, Tang Q, Samdani S, Zhang G, et al. (2005) The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci 25: 2741-2752.
68. Sala C, Piech V, Wilson NR, Passafaro M, Liu G, et al. (2001) Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 31: 115-130.
69. Ronesi JA, Huber KM (2008) Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci 28: 543-547.
70. Aronica E, Dickson DW, Kress Y, Morrison JH, Zukin RS (1998) Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience 82: 979-991.
71. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, et al. (2005) Soluble betaamyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25: 11061-11070.
72. McEwen BS (2001) Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91: 2785-2801.
73. Savaskan E, Olivieri G, Meier F, Ravid R, Muller-Spahn F (2001) Hippocampal estrogen beta-receptor immunoreactivity is increased in Alzheimer's disease. Brain Res 908: 113-119.
74. Schupf N, Lee JH, Wei M, Pang D, Chace C, et al. (2008) Estrogen receptoralpha variants increase risk of Alzheimer's disease in women with Down syndrome. Dement Geriatr Cogn Disord 25: 476-482.
75. Liang K, Yang L, Yin C, Xiao Z, Zhang J, et al. (2010) Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J Biol Chem 285: 935-942.
76. Porrello E, Monti MC, Sinforiani E, Cairati M, Guaita A, et al. (2006) Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur J Neurol 13: 639-644.
77. Ishunina TA, Swaab DF (2010) Decreased alternative splicing of estrogen receptor-alpha mRNA in the Alzheimer's disease brain. Neurobiol Aging.
78. Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, et al. (2007) Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res 41: 174-178.
79. Francis YI, Diss JK, Kariti M, Stephanou A, Latchman DS (2007) p300 activation by Presenilin 1 but not by its M146L mutant. Neurosci Lett 413: 137-140.
80. Weihl CC, Ghadge GD, Miller RJ, Roos RP (1999) Processing of wild-type and mutant familial Alzheimer's disease-associated presenilin-1 in cultured neurons. J Neurochem 73: 31-40.
81. Becker EB, Bonni A (2004) Cell cycle regulation of neuronal apoptosis in development and disease. Prog Neurobiol 72: 1-25.
82. Almeida A, Bolanos JP, Moreno S (2005) Cdh1/Hct1-APC is essential for the survival of postmitotic neurons. J Neurosci 25: 8115-8121.
83. Aulia S, Tang BL (2006) Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer's disease pathology. Biochem Biophys Res Commun 339: 1-6.
84. Citri A, Soler-Llavina G, Bhattacharyya S, Malenka RC (2009) N-methyl-Daspartate receptor- and metabotropic glutamate receptor-dependent long-term depression are differentially regulated by the ubiquitin-proteasome system. Eur J Neurosci 30: 1443-1450.
85. Bamburg JR, Bloom GS (2009) Cytoskeletal pathologies of Alzheimer disease. Cell Motil Cytoskeleton 66: 635-649.
86. Fedulov V, Rex CS, Simmons DA, Palmer L, Gall CM, et al. (2007) Evidence that long-term potentiation occurs within individual hippocampal synapses during learning. J Neurosci 27: 8031-8039.
87. Alkon DL, Sun MK, Nelson TJ (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 28: 51-60.
88. Fu H, Dou J, Li W, Cui W, Mak S, et al. (2009) Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently. Eur J Pharmacol 623: 14-21.
89. Pascale A, Amadio M, Govoni S, Battaini F (2007) The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol Res 55: 560-569.
90. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, et al. (2006) Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98: 1167-1175.
91. Sheng M, Kim E (2000) The Shank family of scaffold proteins. J Cell Sci 113(Pt 11): 1851-1856.
92. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, et al. (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154: 1673-1684.
93. Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61: 154-166.
94. Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51: 1562-1566.
95. Bernardini S, Bellincampi L, Ballerini S, Federici G, Iori R, et al. (2005) Glutathione S-transferase P1 *C allelic variant increases susceptibility for lateonset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem 51: 944-951.
96. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, et al. (2007) Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatry 15: 879-887.
97. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499-509.
98. Guo Q, Fu W, Holtsberg FW, Steiner SM, Mattson MP (1999) Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations. J Neurosci Res 56: 457-470.
99. Querfurth HW, Selkoe DJ (1994) Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 33: 4550-4561.
100. Querfurth HW, Jiang J, Geiger JD, Selkoe DJ (1997) Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. J Neurochem 69: 1580-1591.
101. Green KN, LaFerla FM (2008) Linking calcium to Abeta and Alzheimer's disease. Neuron 59: 190-194.
102. Foster TC (2007) Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6: 319-325.
103. Johnson EM, Jr., Koike T, Franklin J (1992) A ''calcium set-point hypothesis'' of neuronal dependence on neurotrophic factor. Exp Neurol 115: 163-166.
104. Canzoniero LM, Babcock DJ, Gottron FJ, Grabb MC, Manzerra P, et al. (2004) Raising intracellular calcium attenuates neuronal apoptosis triggered by staurosporine or oxygen-glucose deprivation in the presence of glutamate receptor blockade. Neurobiol Dis 15: 520-528.
105. Mattson MP, Chan SL (2003) Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34: 385-397.
106. Trotti D, Danbolt NC, Volterra A (1998) Glutamate transporters are oxidantvulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 19: 328-334.
107. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, et al. (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2: e536.
108. Drago D, Cavaliere A, Mascetra N, Ciavardelli D, di Ilio C, et al. (2008) Aluminum modulates effects of beta amyloid(1-42) on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res 11: 861-871.
109. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.